Griadil, T.I.Chopey, I.V.Chubirko, K.I.Hechko, M.M.Rumaneh, W.2021-07-292021-07-292021Griadil TI, Chopey IV, Chubirko KI, Hechko MM, Rumaneh W. Assessment of cardiovascular risk in patients with Type 2 diabetes mellitus and associated obesity and ways of its correction. Wiadomosci lekarskie. 2021;74(4):998-1002. doi: 10.36740/WLek202104135.https://essuir.sumdu.edu.ua/handle/123456789/84790The aim: To analyze and calculate CVR in patients with T2DM and concomitant obesity. Materials and methods: The selection of patients was carried out based on the Uzhhorod District Clinical Hospital, in the period from November 2016 to January 2020. All patients were divided into 3 groups: 1 (n=93) with T2DM and concomitant obesity, 2 (n=87) with T2DM, 3 (n=39) with obesity. The treatment period lasted 1 year and included dosed exercise for at least 30 minutes per day and dietary recommendations. Patients in groups 1 and 2 received metformin 850 mg twice daily in combination with dapagliflozin 10 mg once daily. CVR was determined at the time of enrollment and after 1 year of treatment using: American College of Cardiology / American Heart Association Guideline on the Assessment of Cardiovascular Risk (2013) (ASCVD Risk) and Framingham Risk Score (FRS). Results: The data obtained as a result of the study revealed the highest CVR in patients of group 1, in contrast to group 2 and 3 (p<0.05). After 1 year of complex treatment, CVR indicators were statistically significantly reduced in all experimental groups (p<0.05). Conclusions: Determining CVR parameters and exposure to them within 10 years can remove unwanted cardiovascular complications.enCC BY-NC-ND 4.0type 2 diabetes mellitusobesitytreatmentdiagnosticsdapaglifloflozincardiovascular riskArticle